9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

ConditionDiffuse Large B-cell Lymphoma|Follicular Lymphoma|Malignant Rhabdoid Tumors (MRT)|Rhabdoid Tumors of the Kidney (RTK)|Atypical Teratoid Rhabdoid Tumors (ATRT)|Synovial Sarcoma|Epitheliod Sarcoma|Mesothelioma|Advanced Solid TumorsEstimated Enrollment: 300Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: EZH-501Study First Received: August 5, 2016Last Updated: September 13, 2016Estimated Primary Completion Date: December 2023Primary Outcome Measures:Long-term safety profile of tazemetostat measured by number of AEs and duration of exposure to tazemetostat|The overall survival (OS)Sponsors and Collaborators:Epizyme, Inc.Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02875548...

Continue reading

CBT-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

ConditionSolid Tumor|Advanced Cancer|ColoRectal Cancer|Endometrial Cancer|Gastric Cancer|Hepatocellular Cancer|Nonsmall Cell Lung Cancer|Mesothelioma|Ovarian Cancer|Renal Cancer|Nasopharyngeal Cancer|Esophageal Cancer|Gastroesophageal Junction AdenocarcinomaEstimated Enrollment: 50Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: CBT-501-01Study First Received: January 30, 2017Last Updated: March 30, 2017Estimated Primary Completion Date: February 2018Primary Outcome Measures:Number of participants with treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.03) in patients with advance solid tumors|Determine the recommended Phase 2 dose and schedule|Area under the plasma concentration versus time curve (AUC)|Maximum plasma concentration|Time...

Continue reading

Cancer Research Repository for Individuals With Cancer Diagnosis, High Risk Individuals, and Individuals With No History of Cancer (Control)

ConditionPancreatic Cancer|Thyroid Cancer|Lung Cancer|Esophageal Cancer|Thymus Cancer|Colon Cancer|Rectal Cancer|GIST|Anal Cancer|Bile Duct Cancer|Duodenal Cancer|Gallbladder Cancer|Gastric Cancer|Liver Cancer|Small Intestine Cancer|Peritoneal Surface Malignancies|Familial Adenomatous Polyposis|Lynch Syndrome|Bladder Cancer|Kidney Cancer|Penile Cancer|Prostate Cancer|Testicular Cancer|Ureter Cancer|Urethral Cancer|Hypopharyngeal Cancer|Laryngeal Cancer|Lip Cancer|Oral Cavity Cancer|Nasopharyngeal Cancer|Oropharyngeal Cancer|Paranasal Sinus Cancer|Nasal Cavity Cancer|Salivary Gland Cancer|Skin Cancer|CNS Tumor|CNS Cancer|Mesothelioma|Breastcancer|Leukemia|Melanoma|Sarcoma|Unknown Primary Tumor|Multiple Myeloma|Ovarian Cancer|Endometrial Cancer|Vaginal CancerEstimated Enrollment: 9999Age Group: 19 Years to 110 Years   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: ProspectiveStudy ID Numbers: UNMC 253-13Study First Received: December 2, 2013Last Updated: November 14, 2016Estimated Primary Completion Date: December 2099Primary Outcome Measures:Development and implementation of a web-based Cancer Collaborative Registry...

Continue reading

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

ConditionCarcinoma, Non-Small-Cell Lung|Mesothelioma|Bladder Cancer|Ovarian Cancer|Peritoneal Cancer|Thymoma|Thymus Cancer|Uterine Cervical CancerEstimated Enrollment: 24Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: UCCI-EXP-16-01Study First Received: January 13, 2017Last Updated: January 13, 2017Estimated Primary Completion Date: January 2020Primary Outcome Measures:Dose-limiting toxicity of the combination of bosutinib and pemetrexed|Maximum tolerated dose of the combination of bosutinib and pemetrexed|Adverse events of the combination of bosutinib and pemetrexed|Anti-tumor response rate|Progression-free survivalSponsors and Collaborators:Nagla Karim|University of CincinnatiResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT03023319...

Continue reading

Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials

ConditionLymphoma|Thorasic Cancers|Prostate Cancer|LeukemiaEstimated Enrollment: 360Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Case-Control|Time Perspective: Cross-SectionalStudy ID Numbers: 170010|17-CC-0010Study First Received: October 27, 2016Last Updated: April 21, 2017Estimated Primary Completion Date: August 28, 2019Primary Outcome Measures:Traumatic Stress SymptomsSponsors and Collaborators:National Institutes of Health Clinical Center (CC)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02948413...

Continue reading

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

ConditionMalignant Mesothelioma|Pancreatic Cancer|Ovarian Tumor|Triple Negative Breast Cancer|Endometrial Cancer|Other Mesothelin Positive TumorsEstimated Enrollment: 20Age Group: 18 Years to 70 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: s2015-080-06Study First Received: October 19, 2015Last Updated: October 19, 2015Estimated Primary Completion Date: November 2017Primary Outcome Measures:Occurrence of Study related adverse events|Anti-tumor responses to CART-meso cell infusionsSponsors and Collaborators:Chinese PLA General HospitalResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02580747...

Continue reading

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

ConditionPulmonary Metastases From Cancers|Mediastinal or Chest Wall Neoplasms|Malignant Pleural Mesotheliomas NOS|Esophageal Cancers NOS|Lung Cancer NOSEstimated Enrollment: 800Age Group: up to 100 Years   (Child, Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Case-Only|Time Perspective: ProspectiveStudy ID Numbers: 060014|06-C-0014Study First Received: October 20, 2005Last Updated: April 21, 2017Estimated Primary Completion Date: nullPrimary Outcome Measures:Permit evaluation of patients referred to the Thoracic Surgery Section, of the Thoracic and GI Malignancies Branch, NCI in order to identify individuals who will be suitable candidates for clinical research protocols|To obtain specimens for researchSponsors and Collaborators:National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Result...

Continue reading

Rapid Autopsy and Procurement of Non-Small Cell Lung Cancer Tissue

ConditionThymus Tumors|Mesothelioma|Non- Small Cell Lung Cancer|Small Cell Lung CancerEstimated Enrollment: 72Age Group: 18 Years to 100 Years   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: ProspectiveStudy ID Numbers: 130131|13-C-0131Study First Received: May 8, 2013Last Updated: April 21, 2017Estimated Primary Completion Date: December 29, 2017Primary Outcome Measures:Procurement of primary and metastatic tissue of thoracic malignancies shortly after death in order to investigate tumor heterogeneity- both intratumor and between paired primary and metastatic site, using integrated genomic and proteomic analysi...

Continue reading

Peritoneal Surface Malignancies – Characterization, Models and Treatment Strategies

ConditionPseudomyxoma Peritonei.|Colorectal Carcinoma.|Ovarian Carcinoma.|Mesothelioma.Estimated Enrollment: 200Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: ProspectiveStudy ID Numbers: PSM_250913Study First Received: February 17, 2014Last Updated: October 14, 2015Estimated Primary Completion Date: January 2017Primary Outcome Measures:Overall survival (OS)|Progression-free survival (PFS)Sponsors and Collaborators:Oslo University Hospital|The Research Council of NorwayResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02073500...

Continue reading

Pemetrexed and Erlotinib for Metastatic Colorectal Cancer

ConditionMetastatic Colorectal CancerEstimated Enrollment: 50Age Group: 19 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 4-2015-0617Study First Received: March 9, 2016Last Updated: July 12, 2016Estimated Primary Completion Date: July 2017Primary Outcome Measures:Overall response rate|Progression-free survival|Overall survival|Disease control rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Sponsors and Collaborators:Yonsei UniversityResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02723578...

Continue reading